RyboDyn, Inc., a biotechnology company pioneering immunotherapies targeting the dark proteome, has been selected to join Lilly Gateway Labs (LGL) in San Diego, an innovation hub operated with Alexandria Real Estate Equities, Inc. This selection provides RyboDyn with direct access to Lilly’s global scientific and business network to advance its lead programs. Through its sequencing and AI-driven platform, RyboCypher, RyboDyn has uncovered a new class of therapeutic targets that are cance...